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research and practice. In this article, the authors introduce a framework of four interrelated themes
in prognosis research, describe the importance of the first of these themes (understanding future
outcomes in relation to current diagnostic and treatment practices), and introduce recommendations
for the field of prognosis research
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In clinical medicine, the term prognosis refers to the risk of
future health outcomes in people with a given disease or health
condition. Prognosis research is thus the investigation of the
relations between future outcomes (endpoints) among people
with a given baseline health state (startpoint) in order to improve
health (see supplementary figure on bmj.com). The study of
prognosis has never been more important, as globally more
people are living with one or more disease or health impairing
condition than at any previous time.1 For this reason,
governments across the world are increasing their interest in
the outcomes of healthcare currently provided for people with
disease.2 Similarly, research funders and researchers are
increasingly focused on translating new interventions and
technologies from the laboratory to clinical practice and then
healthcare policy in order to establish and implement new
standards of high quality care and improve patient outcomes.
Prognosis research findings should thus be integral to clinical
decision making, healthcare policy, and discovering and
evaluating new approaches to patient management. However,
there is a concerning gap between the potential and actual impact
of prognosis research on health. Prognosis research studies too
often fall a long way short of the high standards required in
other fields, such as therapeutic trials and genetic epidemiology.
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In the PROGnosis RESearch Strategy (PROGRESS) series
(www.progress-partnership.org), we propose a framework of
four distinct but inter-related prognosis research themes:
(1) The course of health related conditions in the context of
the nature and quality of current care (fundamental prognosis
research)
(2) Specific factors (such as biomarkers) that are associated
with prognosis (prognostic factor research)3
(3) The development, validation, and impact of statistical
models that predict individual risk of a future outcome
(prognostic model research)4
(4) The use of prognostic information to help tailor treatment
decisions to an individual or group of individuals with similar
characteristics (stratified medicine research).5
Figure 1⇓ illustrates these four prognosis research areas for
women with breast cancer (startpoint) and the endpoint of death
or disease-free survival. Part (a) shows country variations in
age adjusted, five year survival (fundamental prognosis
research)6; part (b) shows survival curves according to the value
of extracellular domain of human epidermal growth factor
receptor 2 (HER2 ECD), which is identified to be prognostic
of disease outcome (prognostic factor research)7; part (c) shows
the use of multiple clinical variables within a statistical model
to estimate individual risk of a particular endpoint (prognostic
model research)8; and part (d) shows why a positive oestrogen
receptor status is used to identify those who will benefit from
tamoxifen therapy (stratified medicine research).9
The overarching aim of the PROGRESS series is to explain
how each of these four prognosis research themes provides
important evidence that can be used at multiple (translational)
pathways toward improving clinical outcomes—from the
discovery of new interventions, through to their evaluation and
implementation in the clinical management of individual
patients, and to examining the impact of interventions and
healthcare policies on patient outcomes. This contrasts with
previous reviews of prognosis research which consider impact
at one end of the translational spectrum (such as clinical decision
making) or on just one type of prognosis question (such as
prognostic models10). Whereas previous reviews focus on one
specific disease area (such as cancer),11 12 we include examples
from cancer, cardiovascular disease, musculoskeletal disorders,
trauma, and other conditions. Our series describes the current
challenges and opportunities in the field and makes
recommendations for necessary improvements to move toward
a clearer map for prognosis research that ultimately improves
patient outcomes (summarised in supplementary table 1 on
bmj.com).
An important place to start is with research that aims to examine
the outcomes of a disease or health condition in the context of
current clinical practice, and this we term fundamental prognosis
research. In this first article we consider what this entails,
explain its importance in pathways toward improving patient
outcomes, and outline a set of recommendations with the aim
of improving the quality and impact across all of the inter-related
themes in prognosis research and which will be expanded in the
other articles in our series.
What is fundamental prognosis research?
Before carrying out research into novel prognostic factors,
prognostic models, or stratified medicine it is necessary to carry
out research describing and explaining future outcomes in people
with a disease or health condition in relation to current
diagnostic and treatment practices. There is a close relation
between the questions “What is the prognosis of people with
this condition?” and “What are the outcomes of the care which
people receive for this condition?” In order to improve the
quality of healthcare, evidence is required on how the specific
patterns of care received (such as investigation, treatment,
support), and their variations (such as underuse, overuse, misuse)
have an impact on future endpoints.13 Such research has a broad
remit. It spans, for example, investigations into societal
influences (inequitable variations in care and outcome among
older people, women, the socially disadvantaged, and ethnic
minorities), patient safety,14 15 unanticipated harms and benefits
from treatments, and screening research. Prognosis in the
absence of care—which is sometimes termed natural history—is
an important parameter for judging the potential impact of
screening for asymptomatic disease (such as mammography for
breast cancer), as well as for case detection of symptomatic
undiagnosed or unpresented conditions such as back pain or
angina.16 17
These relations may be expressed as an absolute risk (or rate)
of one or more type of endpoint among groups of people who
share demographic and clinical characteristics; some refer to
this as an average prognosis in a particular group of interest, or
as a baseline risk. Here the research provides initial answers to
the question “What is the prognosis of people with a given
disease?” For example, on average about 15% of people aged
65 years or older, admitted in 2006 in the US died within 30
days of admission to hospital with a heart attack compared with
an average of 19% in 1995.18 Such a change in the average
mortality rate is illustrated in figure 2⇓. This shows the
decreasing prognostic burden of heart attack and motivates
inquiry into new approaches to understand and reduce this risk
further. This clinical scenario also exemplifies that “the
prognosis” of a disease or condition is a somewhat misleading
expression: what is observed is prognosis of people in particular
clinical contexts, defined by current clinical approaches in
diagnosing, characterising, and managing patients with a
symptom or disease.
Such prognosis research is also concerned with describing and
understanding the variations around the average course.19 20
These variations may occur between individual patients or
between patients clustered, for example, within surgeons,
hospitals, or regions. The acute myocardial infarction example
above demonstrates striking variations between hospitals in
prognosis, and similar variations are seen in traumatic brain
injury and other conditions.18 21 Indeed, for most hospitals the
national average is a poor guide to the mortality of their patients
(fig 2⇓).
Stephen J Gould, the evolutionary biologist, having survived
20 years after being told the median survival of his abdominal
mesothelioma was eight months, famously remarked, “the
median isn’t the message.”22 Describing and explaining the
sources of variability in prognosis is a theme throughout our
PROGRESS framework.3-5 Fundamental prognosis research
may help explain Gould’s long survival in terms of the
demographic and clinical context (for example, his high
educational status and the quality of care received), whereas
research into emerging prognostic factors may examine
psychological, behavioural, or biomarker factors associated with
improved outcome (see paper 2 in our series3), or the extent to
which his survival was predictable from statistical models of
individual risk prediction (paper 3 in our series4), or whether
particular treatments had a larger beneficial effect for him than
for others (paper 4 in our series5).
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Importance of fundamental prognosis
research in the pathways toward improved
health outcomes
Healthcare professionals, people with a disease or health
condition, funders, and policy makers require valid, reliable
evidence about the outcomes of diseases and health conditions
in order to make decisions. Here we review the potential impact
of such evidence across translational pathways in healthcare,
starting from the applied, healthcare delivery end (far right of
pathways schema shown at bottom of figs 2⇓, 3⇓, and 4⇓) and
working back to discovery and new approaches (far left of
schema).
Importance for public health policy
Public health policy makers need estimates of average prognosis
to model the population burden of diseases and assess the
relative contribution of healthcare delivery among those with
disease (secondary prevention) and without disease (primary
prevention). For example, the public health objective of reducing
overall coronary heart disease mortality (a conflation of
incidence of non-fatal coronary disease and subsequent death)
has been helped by modelling the impact of population
interventions aimed at early detection and primary and secondary
prevention.23-25 Such models use an average prognosis of heart
attack survival from the date of diagnosis among age and sex
strata to attribute quality adjusted life years (and health service
costs of managing the disease) which would be saved with
successful prevention.
By contrast with the improvements over time in the prognosis
of coronary disease, for people with low back pain there is little
evidence that the average prognosis (based on symptom relief
26 27) has changed over the past 20 years, nor does it differ
between countries with different healthcare systems.28 This
suggests that healthcare itself is not a major influence on average
symptomatic outcome in people with back pain. However, when
considering the outcome of sickness absence, there are dramatic
variations over time and between countries—suggesting the
importance of the broader public health context of working
patterns and benefit payments for chronic illness.29
Importance for comparative effectiveness and
health services research
Insights into health and healthcare policy may come from
comparing the prognosis of specific conditions over time and
place in order to assess the comparative effectiveness of systems
of care.30 31 For example, figure 1⇓ shows that the five year
survival from breast cancer in 2000-03 varies widely from
country to country (from about 70% in the Czech Republic to
90% in Iceland). The UK seems to have worse cancer survival
than most other European countries,32 and the latter have worse
survival for some cancers than the US. Such international
comparisons of average prognosis provide a motivation for
researchers to uncover explanations and for healthcare policy
makers to improve the quality of care and deliver better health
outcomes.2 Policy makers seeking to improve national cancer
outcomes may consider a range of interventions, including:
early detection (such as mammography screening),
population-wide guidance (such as encouraging self
examination),33 34 centralisation of services, and systematic
implementation of cost effective therapies. Ecological
comparisons of country-level factors (such as smoking
prevalence or number of specialists per capita population) can
be related to outcomes. Such research may generate hypotheses
for prognostic factor research (see paper 2 in our series3) as well
as helping to formulate service and policy development.
Fundamental prognosis research is vital in addressing the
“second gap” in translation,35 in which evidence from
randomised trials of effective treatments may fail to be
implemented in usual clinical practice (far right of translational
pathway toward improved clinical outcomes). For example, the
between hospital variations in outcome from acute myocardial
infarction (fig 2⇓) may, in part, stem from differing use of
evidence based therapies. These findings have profound
implications for healthcare policy. It demonstrates a “normal
distribution” of mortality between hospitals; over time the whole
distribution of hospital mortality improves and shifts to the left
and the variation between hospitals in outcomes narrows. The
policy implication is that improvements in the quality of care
in the population of all hospitals may have contributed to the
observed shift in the average prognosis. Thus the evidence did
not support a contrasting policy alternative of focusing on the
identification of, and remedial action in, outlying poor
performers.36 Here prognosis research is contributing evidence
about health services and is managing knowledge generated
from electronic health records. Such evidence35 informs policy
choices which are themselves highly unlikely to be subjected
to randomised trials.37
Importance for health technology assessment
of imaging and other tests
A key target for translational research is the development of
new clinical imaging andmolecular markers whichmay identify
patient phenotypes in such a way as to lead to improved
outcomes. Such new technologies may change the spectrum of
diagnosed disease, and the question is whether prognosis is the
same as with the use of standard tests and whether the balance
of benefit and harm of treatment remains the same. For example,
for decades exercise electrocardiography has been used in the
characterisation of patients with stable chest pain, and recent
guidelines recommend the use of an emerging technology,
non-invasive computed tomographic coronary angiography, in
some patients.38 Since event powered randomised trials of
imaging remain rare, fundamental prognosis research provides
an important method of health technology assessment.39
Importance for trials and decision models
Estimates of average prognosis are also crucial for the rationale,
design, interpretation, and impact modelling of trials of an
intervention to improve prognosis. For example, prognosis
research among people with angina shows that 50% of people
with existing therapies have recurrent or persistent symptoms,40
suggesting the need for trials of new interventions. Reliable
estimates of prognosis inform the estimates of likely accrual of
endpoints in the trial arms (such as expected proportion
experiencing an event by a particular time), and hence facilitate
statistical sample size calculations. They also contribute to the
interpretation in terms of generalisability of clinical trial results,
as one can compare the average prognosis of patients in the trial
without treatment with the average prognosis in particular
populations.
Importantly, in order to translate relative treatment effects (such
as relative risks or hazard ratios) back to the absolute scale, one
needs to know the average prognosis (baseline risk) in the
untreated group. One can then talk in terms of the reduction in
probability of a poor outcome (risk difference), which leads to
clinically informative measures such as the number needed to
treat in order to save one patient from a particular poor outcome.
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Absolute effects are used within decision models and cost
effectiveness analyses, which are highly influential to decision
makers such as the National Institute of Health and Clinical
Excellence (NICE). Suchmodels combine parameters of average
prognosis along with estimates of treatment effects and costs.
Conclusions from these models are often particularly sensitive
to the accuracy of the data on average prognosis among those
without the specific treatment of interest.
Importance for newapproaches,mechanisms,
and targets for trials
Fundamental prognosis research may provide insights beyond
evaluating the status quo of clinical care. Estimating the
prospective associations between two diseases has led to startling
discoveries that have stimulated the development of new
interventions and new clinical trials that have ultimately changed
clinical practice. For example, few foresaw that a prognostic
consequence of Helicobacter pylori infection was peptic ulcer
before the Nobel prize winning work that established the link
and subsequent antibiotic trials.41 Importantly, the outcomes of
uncommon conditions may give insights into disease
mechanisms of common conditions. For example, the increased
risk of coronary outcomes among people with familial
hypercholesterolaemia focused interest on the low density
lipoprotein cholesterol pathways which are important in
coronary disease experienced by people without this genetic
disorder and contributed to the development of lipid lowering
therapy.
Taking a broad view of prognostic outcomes may generate new
knowledge at the start of translational pathways with (as yet)
unknown implications for developing new interventions.
Consider the example of following up people with Parkinson’s
disease. The risk of cancer is not an endpoint that would
conventionally be considered. However, a meta-analysis found
that the risk of cancer was significantly reduced compared with
people without Parkinson’s disease (fig 3⇓).42 This raises the
question whether specific characteristics of Parkinson’s disease
that explain this apparent protective effect can be identified,
and whether this might lead to new intervention targets. There
are probably many prognostic associations between two or more
diseases that have yet to be uncovered. Some have proposed
that approaches using all available clinical data (so called
phenome-wide scans), agnostic to any prior theories about
mechanism, might identify new associations between
conditions.43
Importance for overcoming the limitations of
diagnosis
The understanding of future outcome risk (prognosis) may be
a more useful way of formulating clinical problems than
pursuing diagnosis for several reasons. First, subjectively
reported illness such as mental health problems and pain
syndromes is often managed more with prognostic than
diagnostic labels.44 For example, a physician may reasonably
say to a person presenting with back pain, “I do not know what
is wrong, but I do know that this is the sort of back pain that is
very likely to get better quickly.” Evidence from prognosis
research has helped to redefine low back pain. Spinal
radiography and magnetic resonance imaging contribute little
to understanding the average prognosis of most back pain,16 45
but the duration of symptoms at presentation in primary care is
strongly related to outcome. Figure 4⇓ shows that the chance
of reduced disability at one year is about 70% in those with a
shorter duration (<3 years) of symptoms at presentation versus
40% in those with a longer duration.26-46 Clinical practice
guideline recommendations use symptom duration to guide
management decisions.47 Symptom duration is associated with
clinical outcome and is thus a prognostic factor (see paper 2 in
our series3), which has resulted in it being a standard component
of the clinical evaluation of back pain.
Second, fundamental prognosis research can take a holistic view
of all comorbidities that a person experiences, whereas diagnosis
implies a focus on a single organ system or pathology. The
prognosis of some cancers, traumatic brain injury, and back
pain are importantly influenced by conditions not related to the
tumour, brain, and spine respectively. Third, diagnosis implies
a dichotomy (case v not at a single point in time), which may
be a misleading basis for clinical decision making. For example,
in many countries the decision to lower blood cholesterol is not
based on a diagnosis of hypercholesterolaemia but on thresholds
of continuous risk, determined by age, sex, smoking, blood
pressure, and lipids (see paper 3 in our series4). Such
observations have led to the radical proposition that the
dichotomous, cross sectional snapshot of diagnostic practice
may become redundant, as clinicians increasingly have access
to continuous measures of future risk.48 49
Importance for discovering new diseases
Fundamental prognosis research drives definitions of the
diseases for which interventions are sought.50 Such research
helps define our current view of what distinct clinical conditions
exist and what role new clinical tests might have in changing
our classification of disease entities (nosology). The question
“what is the prognosis of this condition?” is intimately related
to the question “what is this condition?” For example, the entity
of non-fatal myocardial infarction was identified only after many
decades of clinical prognostic observation that symptoms of
chest pain may precede death, replacing the view that the disease
of myocardial infarction was inevitably and instantly fatal. More
recently, prognosis research has helped to redefine non-fatal
acute myocardial infarctions51 based on the presence or absence
of ST elevation, a predictor of differential response to therapy,
and serum troponin measurement. Figure 5⇓ shows that
examination of survival patterns differentiates clinical
phenotypes among people admitted with suspected non-fatal
myocardial infarction. An example of a newly recognised
genetic disorder discovered through prognostic observation is
Brugada syndrome in which an ST elevation pattern on resting
electrocardiogram is associated with sudden death.52
Recommendations for improving the
quality and impact of prognosis research
For each of the four themes of prognosis research to achieve its
potential for improving clinical outcomes, important challenges
need to be addressed and opportunities seized in prognosis
research as a whole. The research community needs to address
serious flaws in the design, conduct, and reporting of prognosis
studies and to recognise the clinical value of reliable prognostic
evidence. In the PROGRESS series we thus make
recommendations for progress in the field, and these are
summarised in supplementary table 1 on bmj.com. Here we
introduce recommendations that cut across the different research
themes. In papers 2–4 in the PROGRESS series,3-5 we discuss
the other recommendations from supplementary table 1. These
recommendations add to, and further specify, those which we
have previously made in the BMJ.53
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Fuelling changes in medicine and healthcare
As shown in the examples above, improvements in electronic
health records, clinical imaging, and “omic” technologies
(genotyping and phenotyping) are beginning to challenge current
disease taxonomy, the focus of much healthcare policy on
process (rather than clinical outcomes), and the clinical
preoccupation with diagnosis (rather than risk). There should
be a formative shift in clinical practice, healthcare policy, and
translational research based on evidence from prognosis
research—that is, the prospective relationships between the
phenotypic, genomic, and environmental assessment of people
with a given startpoint and subsequent endpoints
(recommendation 1 in supplementary table 1). Over their life
course, individuals develop multiple diseases (both distinct and
related) that often do not respect the current organisation of
medical research or practice. There should be new programmes
of prognosis research that bridge multiple clinical specialties,
health systems, pathological mechanisms, and biological systems
and that put the whole patient across his or her “journey” as the
central unit of concern (recommendation 2).
Electronic health records
The scope and impact of prognosis research and electronic health
records research (in primary and secondary care, and in disease
and procedure registries) are intimately related. There is
increasing availability of electronic health records in primary54
and secondary care, and disease and procedure registries.
Particularly where such sources can be linked,55 there is the
possibility of examining the “patient journey” with repeated
measures of risk and care in larger populations than are feasible
with bespoke, investigator led studies. Population coverage,
data quality, and the extent of blood, imaging, and other
diagnostic data are all improving. But concerted efforts are
required to harmonise data on startpoints, endpoints, and
populations of interest in order to make temporal and
international comparisons in prognosis. There should be new
programmes ofmethodological and empirical prognosis research
exploiting electronic health records to define, phenotype, and
follow up people with different health related conditions
(recommendation 3).
Visibility of the field
Prognosis research is currently fragmented and not visible as a
distinct entity. Prognosis research should be recognised as a
field of inquiry important in translational research and intrinsic
to the practice of clinical medicine and development of
healthcare policy (recommendation 4). Efforts should be made
to establish prognosis research as a distinct branch of knowledge,
with a set of scientific methods aimed at understanding and
improving health. Evidence about prognosis is somewhat
neglected; such as in medical textbooks, where the focus is on
the effectiveness of therapies, with only brief details given on
average prognosis,56 sometimes as if therapies can be divorced
from the context of clinical care.57 58
Fundamental prognosis research should compare the prognosis
of clinical cohorts with that of the healthy population
(recommendation 5). Relative survival methods are commonly
applied in cancer, but less often in other disease areas. Relative
survival methods model the survival probability of people with
a condition relative to the expected survival without the
condition (obtained from national population life tables stratified
by age, sex, calender year, and other covariates). By comparing
the observed and expected survival, one can estimate the added
risk of mortality due to having the condition rather than not
having it (that is, measure how prognosis is modified by onset
of a disease). Such methods help prognosis research prioritise
which clinical cohorts require the most attention and most
translational research (that is, identify those cohorts whose
prognosis is most changed by disease onset).
The situation for cancer, where estimates of survival are readily
available (such as Surveillance Epidemiology and End Results,
SEER59) is exceptional. Knowledge management in prognosis
seems somewhat chaotic in generation, dissemination, and
accessibility. Difficulties in identifying and accessing
information about prognosis, and evidence from prognosis
research studies, hamper efforts to inform patients and evaluate
the impact of translational efforts to improve outcomes.
Evidence from prognosis research and information about
prognosis should be systematically collated, made easily
accessible, and updated (recommendation 6).
Teaching and training
Undergraduate and postgraduate training do not currently
provide instruction in how to generate or use evidence from
prognosis research. All healthcare professionals should be
trained in the generation and use of prognosis research evidence;
there should be an expansion of training and education
opportunities for those interested in methodological aspects of
prognosis research (recommendation 7).
Patient and public involvement
Questions of prognosis are among themost important to patients,
but the level of patient and public involvement in prognosis
research is low. Patient reported outcomes are important to
clinical decision and policy making but are understudied. For
example, people with angina might reasonably ask “will my
symptoms get better?” yet a recent systematic review of 83
studies found none that reported symptomatic status as an
endpoint (favouring acute coronary events instead).60 Symptom
status is acknowledged as a major determinant of the clinical
decision to recommend revascularisation.61 Prognosis research
using person focused endpoints may yield unanticipated results.
For example, people with rheumatoid arthritis may care more
about fatigue than about the joint pain, on which doctors tend
to focus.62 Patients and the wider public should be more engaged
in the goals and value of prognosis research, appropriate use of
their clinical data, and better integration of patient reported
outcome measures (recommendation 8).
Conclusion
In this first article in the PROGRESS series, we have introduced
a framework of four themes in prognosis research, and outlined
the importance of initial, fundamental prognosis research. This
first theme is central to the practice of medicine; from basic
understanding of the categories we choose to call disease
through to understanding how variations in healthcare influence
the risk of endpoints. As such, it has a broad array of uses for
policy makers, patients, and clinical decisionmaking and should
be considered a core component of prognosis research. To
maximise the impact of each interrelated theme of prognosis
research,3-5 we have begun outlining a set of recommendations
to enhance the prognosis field, including better use of electronic
health records, greater training and public involvement, and a
wider appreciation of the clinical value of prognosis research
findings.
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Summary points
The PROGRESS series (www.progress-partnership.org) sets out a framework of four interlinked prognosis research themes and provides
examples from several disease fields to show why evidence from prognosis research is crucial to inform all points in the translation of
biomedical and health related research into better patient outcomes. Recommendations are made in each of the four papers to improve
current research standards
What is prognosis research? Prognosis research seeks to understand and improve future outcomes in people with a given disease or
health condition. However, there is increasing evidence that prognosis research standards need to be improved
Why is prognosis research important? More people now live with disease and conditions that impair health than at any other time in
history; prognosis research provides crucial evidence for translating findings from the laboratory to humans, and from clinical research
to clinical practice
This first article introduces the framework of four interlinked prognosis research themes and then focuses on the first of the
themes—fundamental prognosis research, studies that aim to describe and explain future outcomes in relation to current diagnostic
and treatment practices, often in relation to quality of care
Fundamental prognosis research provides evidence informing healthcare and public health policy, the design and interpretation of
randomised trials, and the impact of diagnostic tests on future outcome. It can inform new definitions of disease, may identify unanticipated
benefits or harms of interventions, and clarify where new interventions are required to improve prognosis
The other papers in the series are:
PROGRESS 2: PLoS Med 2013, doi:10.1371.journal/pmed.1001380
PROGRESS 3: PLoS Med 2013, doi:10.1371.journal/pmed.1001381
PROGRESS 4: BMJ 2013, doi:10.1136/bmj.e5793
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Figures
Fig 1 Framework of four different types of prognosis research question, illustrated for breast cancer. a) Fundamental
prognosis research: variations between countries in age adjusted, five year survival (with permission from Cancer Research
UK6). b) Prognostic factor research: survival curves showing that patients with “positive” values (>8.9 ng/mL) of the
extracellular domain of human epidermal growth factor receptor 2 (HER2 ECD) have a worse survival than those with
negative values (≤8.9 ng/mL), and thus HER ECD is a potential prognostic factor (from Tsai et al7). c) Prognostic model
research: use of multiple clinical variables in a model to estimate risk of endpoint, and then combined with evidence of
treatment effectiveness to inform clinical decisions (ER=oestrogen receptor) (from Adjuvant! Online8). d) Stratified medicine
research: predictors of differential treatment response identified in randomised trials, showing that the benefit of tamoxifen
is confined to those with positive oestrogen receptor (ER) status (based on data from Early Breast Cancer Trialists
Collaborative Group9)
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;346:e5595 doi: 10.1136/bmj.e5595 (Published 5 February 2013) Page 8 of 11
RESEARCH METHODS & REPORTING
Fig 2 Example of use of fundamental prognosis research to examine variations in outcomes frommedical care: inter-hospital
variation in mortality per 100 population within 30 days of admission with acute myocardial infarction (created using fictional
data for illustration purposes, but based on the findings of Krumholz et al18)
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Fig 3 Example of use of fundamental prognosis research to discover new associations between diseases: cancer among
non-smoking people with Parkinson’s disease (drawn using data from Bajaj et al42). Path element adapted from chart 7.1
in the Cooksey report (2006) http://bit.ly/Ro27rL (made available for use through the Open Government License)
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Fig 4 Example of use of fundamental prognosis research to define clinically relevant subgroups: duration of low back pain
at presentation (<3 or ≥3 years) and the time to improvement of disability disease (drawn using data from Dunn et al46).
Path element adapted from chart 7.1 in the Cooksey report (2006) http://bit.ly/Ro27rL (made available for use through the
Open Government License)
Fig 5 Example of use of fundamental prognosis research to distinguish clinically relevant groups: people admitted with
suspected acute myocardial infarction (results based on an analysis of 180 000 patients in the Myocardial Ischaemia National
Audit Project, A Timmis and H Hemingway personal communication)
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